EA201590475A1 - Тетрациклиновые соединения - Google Patents

Тетрациклиновые соединения

Info

Publication number
EA201590475A1
EA201590475A1 EA201590475A EA201590475A EA201590475A1 EA 201590475 A1 EA201590475 A1 EA 201590475A1 EA 201590475 A EA201590475 A EA 201590475A EA 201590475 A EA201590475 A EA 201590475A EA 201590475 A1 EA201590475 A1 EA 201590475A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetracycline
connections
structural formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EA201590475A
Other languages
English (en)
Other versions
EA031523B1 (ru
Inventor
Сяо-И Сяо
Роджер Б. Кларк
Диана Катарин Хант
Цуйсян Сунь
Магнус Ронн
У-Янь Чжан
Миньшен Хэ
Original Assignee
Тетрафейз Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тетрафейз Фармасьютикалс, Инк. filed Critical Тетрафейз Фармасьютикалс, Инк.
Publication of EA201590475A1 publication Critical patent/EA201590475A1/ru
Publication of EA031523B1 publication Critical patent/EA031523B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению, представленному структурной формулой (I)или его фармацевтически приемлемой соли. Переменные в структурной формуле (I) определены в описании. Также описана фармацевтическая композиция, содержащая соединение структурной формулы (I) или его фармацевтически приемлемую соль, и ее фармацевтическое применение.
EA201590475A 2012-08-31 2013-08-30 Тетрациклиновые соединения EA031523B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695947P 2012-08-31 2012-08-31
PCT/US2013/057690 WO2014036502A2 (en) 2012-08-31 2013-08-30 Tetracycline compounds

Publications (2)

Publication Number Publication Date
EA201590475A1 true EA201590475A1 (ru) 2016-05-31
EA031523B1 EA031523B1 (ru) 2019-01-31

Family

ID=49170898

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590475A EA031523B1 (ru) 2012-08-31 2013-08-30 Тетрациклиновые соединения
EA201891804A EA036088B1 (ru) 2012-08-31 2013-08-30 Тетрациклиновые соединения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891804A EA036088B1 (ru) 2012-08-31 2013-08-30 Тетрациклиновые соединения

Country Status (27)

Country Link
US (3) US9573895B2 (ru)
EP (2) EP2890673B1 (ru)
JP (2) JP6301335B2 (ru)
KR (2) KR102295673B1 (ru)
CN (3) CN108276404A (ru)
AU (3) AU2013308504B2 (ru)
BR (1) BR112015004523B1 (ru)
CA (1) CA2883238C (ru)
CY (1) CY1122744T1 (ru)
DK (1) DK2890673T3 (ru)
EA (2) EA031523B1 (ru)
ES (1) ES2712476T3 (ru)
HK (1) HK1211917A1 (ru)
HR (1) HRP20190268T1 (ru)
HU (1) HUE042600T2 (ru)
IL (2) IL237437B (ru)
LT (1) LT2890673T (ru)
ME (1) ME03329B (ru)
MX (1) MX364400B (ru)
NZ (3) NZ705849A (ru)
PL (1) PL2890673T3 (ru)
PT (1) PT2890673T (ru)
RS (1) RS58572B1 (ru)
SG (2) SG10201801703RA (ru)
SI (1) SI2890673T1 (ru)
TR (1) TR201902057T4 (ru)
WO (1) WO2014036502A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5496202B2 (ja) 2008-08-08 2014-05-21 テトラフェース ファーマシューティカルズ,インコーポレイテッド C7−フルオロ置換テトラサイクリン化合物
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
JP5944825B2 (ja) 2009-08-28 2016-07-05 テトラフェース ファーマシューティカルズ,インコーポレイテッド テトラサイクリン化合物
EP2890673B1 (en) 2012-08-31 2018-11-14 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
CN110167560B (zh) * 2016-08-30 2023-08-18 四相制药公司 四环素化合物和治疗方法
KR102660864B1 (ko) 2016-10-19 2024-04-25 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태
WO2020020999A1 (en) 2018-07-27 2020-01-30 Sandoz Ag Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble api
CN113444070A (zh) * 2021-07-28 2021-09-28 深圳市真味生物科技有限公司 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法
CN115448849B (zh) * 2022-11-10 2023-02-03 苏州富士莱医药股份有限公司 一种2-苄氧基-3-二苄基氨基-5-氟-6-甲基苯甲酸苯酯的制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639292A (ru)
GB935384A (en) 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) * 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) * 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) * 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) * 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) * 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) * 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) * 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) * 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
SG52361A1 (en) 1991-10-04 1998-09-28 American Cyanamid Co Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
CA2103189C (en) 1992-11-17 2005-05-03 Lorne M. Golub Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
WO1995022529A1 (en) 1994-02-17 1995-08-24 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
WO1999037307A1 (en) 1998-01-23 1999-07-29 Trustees Of Tufts College Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
CA2343038A1 (en) 1998-09-28 2000-04-06 Maria Emanuel Ryan A novel inhibitor of cataract formation
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
AU2000257445A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-n-substituted phenyl tetracycline compounds
AU2001271556A1 (en) 2000-07-07 2002-01-21 Trustees Of Tufts College 7,8 and 9-substituted tetracycline compounds
EP2308832B8 (en) 2000-07-07 2019-04-24 Trustees Of Tufts College 9-substituted minocycline compounds
IL153672A0 (en) 2000-07-07 2003-07-06 Tufts College 7-substituted tetracycline compounds
CZ20032780A3 (cs) 2001-03-13 2004-01-14 Paratek Pharmaceuticals, Inc. 7,9- Substituované tetracyklinové sloučeniny
WO2002072031A2 (en) 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
CA2457234A1 (en) 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
ES2338994T3 (es) 2001-04-24 2010-05-14 Paratek Pharmaceuticals, Inc. Compuestos de tetraciclina sustituida para el tratamiento de la malaria.
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2332550A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of neurodegenerative diseases
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
ES2551708T3 (es) 2002-01-08 2015-11-23 Paratek Pharmaceuticals, Inc. Compuestos de 4-desdimetilamino tetraciclina
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
EA200401232A1 (ru) 2002-03-21 2005-12-29 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
CA2502464A1 (en) 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
CA2503446C (en) 2002-10-24 2012-12-18 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
EP2298322A3 (en) 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2005082860A1 (en) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
LT1753713T (lt) 2004-05-21 2016-11-25 President And Fellows Of Harvard College Tetraciklinų ir jų analogų sintezė
CA2585248A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP2008518025A (ja) * 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド 4−アミノテトラサイクリンおよびその使用の方法
AU2006210406C1 (en) 2005-02-04 2013-03-07 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
BRPI0607353A2 (pt) 2005-02-15 2009-09-01 Wyeth Corp composto de fórmula (i); composição farmacêutica; uso do composto para o tratamento ou controle de infecções bacterianas em animais de sangue quente; processo para a preparação de tetraciclinas 9-(n-substituìdas-n-substituìdas-glicil) de fórmulas 5; 7; 10; e tetraciclina 9-(n-substituìda-n-substituìda glicil) de fómulas 5; 7; 10
WO2007014154A2 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
WO2007087416A2 (en) 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
CA2648668C (en) * 2006-04-07 2015-06-23 The President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2026776A2 (en) 2006-05-15 2009-02-25 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
EP2479169B1 (en) 2006-10-11 2014-12-03 President and Fellows of Harvard College Synthesis of Enone Intermediate
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
MX2009006846A (es) 2006-12-21 2009-08-20 Paratek Pharm Innc Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
TWI334106B (en) 2006-12-27 2010-12-01 Icp Electronics Inc Apparatus for converting gray scale and method for the same
JP2010523684A (ja) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
BRPI0813990A2 (pt) 2007-07-06 2011-09-13 Paratek Pharm Innc métodos para sintetizar compostos de minociclina substituìda
WO2009032326A1 (en) 2007-09-07 2009-03-12 Dr. Reddy's Laboratories Ltd. New tetracycline derivatives as antiinfective agents
WO2009128913A1 (en) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2307027A4 (en) * 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
JP5496202B2 (ja) 2008-08-08 2014-05-21 テトラフェース ファーマシューティカルズ,インコーポレイテッド C7−フルオロ置換テトラサイクリン化合物
EP2424834B1 (en) 2009-04-30 2018-07-11 President and Fellows of Harvard College Synthesis of tetracyclines and intermediates thereof
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
EP2427190B1 (en) 2009-05-08 2013-09-18 Tetraphase Pharmaceuticals, Inc. 8-aza tetracycline compounds
WO2010132670A2 (en) 2009-05-13 2010-11-18 Tetraphase Pharmaceuticals, Inc. Pentacycline compounds
JP5944825B2 (ja) 2009-08-28 2016-07-05 テトラフェース ファーマシューティカルズ,インコーポレイテッド テトラサイクリン化合物
CA2790240A1 (en) 2010-03-10 2011-09-15 University Health Network Use of tigecycline for treatment of cancer
CA2799727C (en) 2010-03-31 2018-06-12 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
WO2012021712A1 (en) * 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Tetracycline analogs
WO2012047907A1 (en) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
EP2890673B1 (en) 2012-08-31 2018-11-14 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
MA40836A (fr) 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
CA3011323A1 (en) 2016-01-22 2017-07-27 Sandoz Ag Crystalline eravacycline bis-hydrochloride
CN110167560B (zh) 2016-08-30 2023-08-18 四相制药公司 四环素化合物和治疗方法
KR102660864B1 (ko) 2016-10-19 2024-04-25 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태

Also Published As

Publication number Publication date
NZ745596A (en) 2019-09-27
AU2017200857A1 (en) 2017-03-02
SG10201801703RA (en) 2018-04-27
JP6301335B2 (ja) 2018-03-28
TR201902057T4 (tr) 2019-03-21
PT2890673T (pt) 2019-02-19
US20200048193A1 (en) 2020-02-13
US9573895B2 (en) 2017-02-21
EP2890673A2 (en) 2015-07-08
CN108329312A (zh) 2018-07-27
HUE042600T2 (hu) 2019-07-29
RS58572B1 (sr) 2019-05-31
CA2883238A1 (en) 2014-03-06
ME03329B (me) 2019-10-20
SI2890673T1 (sl) 2019-05-31
PL2890673T3 (pl) 2019-06-28
KR102375238B1 (ko) 2022-03-15
JP2015528468A (ja) 2015-09-28
DK2890673T3 (en) 2019-03-18
MX2015002657A (es) 2015-05-20
AU2013308504B2 (en) 2016-11-10
WO2014036502A2 (en) 2014-03-06
SG11201501516YA (en) 2015-07-30
EA031523B1 (ru) 2019-01-31
EP3461809A1 (en) 2019-04-03
KR20210107184A (ko) 2021-08-31
NZ705849A (en) 2018-06-29
NZ740051A (en) 2019-09-27
US10913712B2 (en) 2021-02-09
HRP20190268T1 (hr) 2019-05-03
EA201891804A1 (ru) 2019-06-28
AU2016247054A1 (en) 2016-11-03
CN104768922B (zh) 2018-04-03
IL237437A0 (en) 2015-04-30
ES2712476T3 (es) 2019-05-13
WO2014036502A3 (en) 2014-04-24
EA036088B1 (ru) 2020-09-25
CA2883238C (en) 2021-11-23
CN108276404A (zh) 2018-07-13
AU2013308504A1 (en) 2015-04-02
KR20150065172A (ko) 2015-06-12
HK1211917A1 (en) 2016-06-03
AU2016247054B2 (en) 2018-08-09
BR112015004523A2 (pt) 2017-07-04
US20170305852A1 (en) 2017-10-26
CN108329312B (zh) 2021-12-31
AU2017200857B2 (en) 2018-11-22
US20160107988A1 (en) 2016-04-21
CN104768922A (zh) 2015-07-08
IL266719A (en) 2019-07-31
JP2018118975A (ja) 2018-08-02
JP6691157B2 (ja) 2020-04-28
KR102295673B1 (ko) 2021-08-27
MX364400B (es) 2019-04-24
BR112015004523B1 (pt) 2020-08-04
LT2890673T (lt) 2019-04-10
US10315992B2 (en) 2019-06-11
CY1122744T1 (el) 2021-03-12
WO2014036502A8 (en) 2014-07-31
IL237437B (en) 2019-09-26
EP2890673B1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
EA201891804A1 (ru) Тетрациклиновые соединения
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
MX2016006336A (es) Compuestos pirazolopirimidina.
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
EA201790661A3 (ru) Ингибиторы вируса гепатита c
EA202190619A1 (ru) Противовирусные соединения
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MD20140072A2 (ru) Новые пиррольные соединения, способ их получения и содержащие их фармацевтические композиции
EA201290632A1 (ru) Производные бетулина
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201591064A1 (ru) Новые производные пиридина
EA201591624A1 (ru) Новые производные пиразола